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Abstract: Rheumatoid arthritis (RA) is an autoimmune disease that affects the synovial cavity of joints,
and its pathogenesis is associated with an increased expression of pro-inflammatory cytokines, namely
tumour necrosis factor-alpha (TNF-α). It has been clinically shown to have an adequate response to
systemic administration of TNF-α inhibitors, although with many shortcomings. To overcome such
limitations, the immobilization of a TNF-α antibody on a nanofibrous substrate to promote a localized
action is herein proposed. By using this approach, the antibody has its maximum therapeutic efficacy
and a prolonged therapeutic benefit, avoiding the systemic side-effects associated with conventional
biological agents’ therapies. To technically achieve such a purpose, the surface of electrospun
nanofibers is initially activated and functionalized, allowing TNF-α antibody immobilization at
a maximum concentration of 6 µg/mL. Experimental results evidence that the biofunctionalized
nanofibrous substrate is effective in achieving a sustained capture of soluble TNF-α over time.
Moreover, cell biology assays demonstrate that this system has no deleterious effect over human
articular chondrocytes metabolism and activity. Therefore, the developed TNF-capturing system may
represent a potential therapeutic approach for the local management of severely affected joints.
Keywords: antibody immobilization; electrospun nanofibers; TNF-α capture; human articular
chondrocytes; rheumatoid arthritis
1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease that affects primarily the synovial cavity
tissues on the small diarthrodial joints of the hands and feet [1], leading to persistent synovial
inflammation [2] and progressive erosion of the articular structures [3,4]. The triggers for the disease
susceptibility and the pathological cascade of events encompass environmental, genetic and stochastic
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factors [3,4]. For example, RA has special incidence on females [5], which is related with genetic [5–7]
and hormonal factors [5,8–10], but also presents a heterogeneous geographic distribution, being less
common in developing countries [11,12], which confirms the involvement of environmental and
socio-cultural factors [12].
The disease pathophysiology involves several interconnected mechanisms. Specific antibodies
for immunoglobulin G (IgG) mediate the autoimmune process, as well as the imbalanced expression
of the pro-inflammatory cytokine’s profile and its functionality [1,12–14]. Consequently, this leads
to inflammatory processes, autoimmunity enhancement, long-term inflammatory synovitis and joint
damage [13,15]. Additionally, locally expressed degradative enzymes digest the cartilaginous matrix
and destroy the articular surfaces [1]. Infiltration of B cells, CD4+ T cells and macrophages into the
synovium, which in normal conditions is relatively acellular [1,14,16], leads to soft tissue oedema and
stiffness [2]. Moreover, other inflammatory cells such as neutrophils, natural killer cells and mast cells
play key roles in the disease’s progression [13].
From the autoimmune disease (AD) subsets that entail the multiple inflammatory cascades, one of
the most significant players is the TNF-α, particularly the over-expression of the TNF-α [11,13,17].
TNF-α, a 233 amino acid protein [18], is a key signaling cytokine in the immune system mainly
produced by monocytes, macrophages [19], and B and T cells [2,13,17]. TNF-α stimulates the
production of other inflammatory mediators, namely IL’s, as well as the recruitment of immune
and inflammatory cells into the joint [20,21]. As a regulatory cytokine that manages communication
between immune cells and controls many of their functions when deregulated, TNF-α plays a key
role in the pathogenesis of chronic inflammatory diseases, such as RA [22,23]. TNF deregulation
in RA is linked to TNF-α converting enzyme (TACE or ADAM17), a metalloproteinase that
cleaves trans-membrane TNF, releasing the soluble segment [18,24]; and to TNF receptors (mostly
TNFr-I) [18,25,26], which are likely to be related with proinflammatory, cytotoxic and apoptotic
responses [2].
The increasing knowledge on RA pathogenesis stimulated the development of different
therapeutic modalities aiming to avoid joint destruction, minimize the symptomatic profile,
and enhance physical function [27]. These options comprise analgesics, symptomatic management and
inflammatory drugs [11,28]. Analgesics enclose the non-steroidal anti-inflammatory drugs (NSAIDs)
that are commonly used to treat RA. The inflammatory suppressive drugs include glucocorticoids and
disease-modifying anti-rheumatic drugs (DMARDs) both non-biologic and biologic. Due to the disease
heterogeneity, therapeutic strategies must be tailored to the individual patient in order to achieve a low
level of disease activity within a limited period of time [29]. Thus, the combination of two treatment
modalities has been proposed to achieve such a purpose [30].
Considering the significant involvement of TNF-α in RA, as well as the rising evidences that
this cytokine heads the pro-inflammatory cytokine cascade, it becomes a significant therapeutic
target [31,32]. Specifically, these evidences led to the development of TNF inhibitors for the treatment
of ADs [33–37], as they became the first class of biologic agents to be used in RA treatment [38].
A specific high affinity monoclonal antibody is used to recognize and neutralize selectively its antigen,
i.e., TNF-α [18,27,39]. Five different types of TNF-α inhibitors are currently licensed for human
clinical use in RA treatment, namely Infliximab, Entarnecept, Adalimumab, Certalizumab Pegol and
Golimumab. With the exception of Infliximab, which is administrated by intravenous (IV) infusion,
all other medicines are administered subcutaneously [13]. For long-term control of RA, a continuous
treatment is required because of disease flares’ risk when the therapy is discontinued [1]. Although
these therapeutic modalities have been used for quite some time, they present many shortcomings such
as lack of specificity, limited antibody half-life, high cost, response variability, or even lack of response
to treatments [11,40]. Due to the systemic character of these treatments, not only target tissues but also
healthy tissues are exposed to a significant dose of drug, leading to adverse side effects [41]. These
effects are common to many tissues, organs and systems, such as cardiovascular, renal, dermatological,
and neurological, or risk of severe infection [11,27,28,40].
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Furthermore, some attention has been given to drug carriers, in order to maintain effective
concentration levels in plasma for extended periods [41]. Examples of these systems are the
encapsulation of Infliximab in polylactide-co-glycolide microspheres [42] or porous silicon 3D
structures [43], as well as long-term release of Etanercept by polyelectrolyte complex formulated
particles [44]. Despite the promising preliminary results, these systems are still poorly developed.
Considering the shortcomings of these treatments, there is a need for innovative approaches
that circumvent the aforementioned adverse side effects. Therefore, the main objective of this
work was to develop an implantable system capable of capturing excessive TNF-alpha present in
intra-articular cavities of an RA patient. For that, we immobilized a neutralizing TNF-α antibody
at the surface of a polymeric substrate (i.e., electrospun nanofibers). This strategy takes advantage
of specific interactions between the antibody and the antigen, where the antibody (TNF-α antibody)
binds to the antigen (TNF-α) avoiding/limiting its harmful pro-inflammatory effects. After the
system´s assembly and proved ability to capture TNF-α secreted by activated monocyte-derived
macrophages, the cytotoxicity of the biofunctionalized system was tested with human articular
chondrocytes. Indeed, the cytocompatibility and chondrogenic differentiation potential of bare
electrospun nanofibers were previously reported by us [45–47], corroborating their potential use
in cartilage regeneration approaches.
2. Materials and Methods
2.1. Materials
Polycaprolactone (PCL; Mn = 70,000–90,000 determined by Gas Permeation
Chromatography), chloroform, N,N-dimethylformamide (DMF), 1,6-hexamethylenediamine
(HMD), Ellmans reagent (DTNB), 2-iminiothiolane (2IT), 2-(N-morpholino)-ethanesulfonic
acid (MES hydrate), phosphate buffered saline (PBS), N-hydroxysuccinimide (NHS),
and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) were purchased
from Sigma-Aldrich (Saint Louis, MO, USA) and kept at room temperature (RT), with the exception of
2IT which was kept at 4 ◦C and EDC which was kept at −20 ◦C. 4-(dimethylamino) pyridine (DMAP)
was purchased from Millipore (Darmstadt, Germany) and kept at RT. Anti-TNF-α antibody [B-C7] was
purchased from Abcam (Cambridge, UK) and kept at 4 ◦C until further use. Alexa Fluor® 488 goat
anti-mouse rabbit IgG (H + L) and TNF-α human ELISA kit were purchased from Life Technologies
(Carlsbad, CA, USA) and kept at 4 ◦C until further use.
2.2. Production and Functionalization of Nanofiber Meshes
2.2.1. Production of Nanofiber Meshes
Nanofiber meshes (NFMs) were prepared as described elsewhere [48,49]. Briefly, the NFMs were
produced by electrospinning of a polymeric solution of 15% (w/v) PCL dissolved in an organic solvent
mixture of chloroform and dimethylformamide (7:3 ratio). This PCL solution was electrospun by
applying a voltage of 12 kV, a needle tip-to-ground collector distance of 20 cm and a flow rate of
1 mL/h. After the complete processing of 1 mL of PCL solution, the NFMs were left to dry for 1 day at
RT inside a chemical hood, in order to completely evaporate the solvents. All further tests described
were performed in samples of 10-mm squares.
2.2.2. Surface Functionalization of Electrospun NFMs
The surface functionalization of electrospun NFMs was performed as described elsewhere [48,49].
Briefly, the NFMs’ surface was activated by 4 min of UV-Ozone irradiation (UV-O-Cleaner®,
ProCleaner 220, Bioforce Nanoscience, Salt Lake City, UT, USA). Afterwards, the amine groups (–NH2)
were inserted by immersion of the irradiated NFM in a 1 M hexanediamine (HMD) solution during
1 hour at 37 ◦C.
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2.2.3. Quantification of Amine Groups Present at the Functionalized NFMs
Quantification of amine groups present in each NFM was performed as described
elsewhere [50,51]. For that, SH groups were inserted at the surface of the aminolysis-treated NFMs
through the reaction of the amine groups with a 20 mM 2IT solution (0.1 mM PBS at pH8) and with a
20 mM DMAP solution during 1 h at 37 ◦C. Ellman’s reagent method was used to quantify the amino
groups. For that, samples were immersed in 0.1 mM DTNB solution (in PBS 0.1 mM at pH 7.27) and
incubated during 1 h at 37 ◦C. The absorbance of supernatants was measured in triplicate at 412 nm
in a quartz plate, using the DTNB solution as blank. For the calculation of the 2-nitro-5-thiobenzoate
(NTB−2) molar absorption coefficient, the value of 14,151 M−1 cm−1 was used [50,51].
2.3. Antibody Immobilization
The TNF-α antibody was immobilized at the surface of activated and functionalized
electrospun NFMs. To determine the substrate’s maximum immobilization capacity, a wide range
of primary antibody concentrations were considered (from 0 to 12 µg/mL). The TNF-α antibody
was firstly activated by a 15-minute incubation with a solution of EDC/NHS (50 mM EDC and
200 mM NHS), dissolved in a 0.1 M 2-(N-morpholino)-ethanesulfonic acid (MES) buffer with 0.9%
(w/w) NaCl, followed by pH adjustment to 4.7 [48].
The functionalized NFMs were incubated with 200 µL of the activated TNF-α antibody overnight
at 4 ◦C. Biofunctionalized NFMs were washed three times with PBS. A 3% bovine serum albumin (BSA)
solution was used as a blocking step. To determine the degree of TNF-α antibody immobilization,
biofunctionalized NFMs were incubated with an Alexa Fluor® 488 solution diluted in PBS (1:200
ratio). As a negative control, NFMs with no antibody immobilized (plotted as 0 µg/mL) were used.
The fluorescence of the supernatant was determined in triplicate, using an excitation of 495/20 nm
and an emission of 519/20 nm, and used to quantify the amount of antibody effectively immobilized.
2.4. Characterization Biofunctionalized NFMs
2.4.1. Scanning Electron Microscopy (SEM)
SEM was used to analyse the morphology of biofunctionalized NFMs. Briefly, the biofunctionalized
NFMs were sputter-coated with a thin layer (9–12 nm) of gold/palladium (Cressington 208 HR) and
then analysed by SEM (NanoSEM, Nova 200, FEI company, Hillsboro, OR, USA). Micrographs were
recorded at 15 kV with magnifications ranging from 100 to 2000 times.
2.4.2. Fluorescence Microscopy
A fluorescence microscope (Axio Imager Z1m, Zeiss, Gottingen, Germany) was used to analyze
the spatial distribution of the TNF-α antibody at the surface of electrospun NFMs. The TNF-α antibody
was linked by a secondary antibody with green fluorescence (Alexa Fluor™ 488). Photographs were
recorded at magnifications of 50, 200 and 400 times.
2.5. Capturing of TNF-α Present in Conditioned Medium of Macrophage Culture
A human monocytic cell line THP-1 was maintained in RPMI 1640 media supplemented
with 2 mM L-glutamine, 100 µg/mL of penicillin, 100 µg/mL of streptomycin, 10 mM HEPES,
and 10% fetal bovine serum (complete RPMI, cRPMI) (Life Technologies, Carlsbad, CA, USA). For the
induction of cell differentiation, cells (106 per mL) were seeded in cRPMI with 100 nM phorbol
12-myristate-13-acetate (PMA) for 24 h. After incubation, non-attached cells were removed by
aspiration, and the adherent cells were washed three times with cRPMI. To ensure reversion of
cells to a resting macrophage phenotype before stimulation, cells were incubated for an additional
48 h in cRPMI without PMA. For stimulation and retrieval of conditioned media, cells were further
incubated for 4 h with 100 ng/mL of lipopolysaccharide (LPS) in fresh cRPMI and the supernatants
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were collected and stored at −80 ◦C. Production of TNF-α was assessed in the conditioned media
by commercial ELISA (Life Technologies, Carlsbad, CA, USA). Four systems were tested at least in
quadruplicates, in two independent assays: (1) the biofunctionalized NFM (with immobilized TNF-α
antibody); (2) a positive control with the soluble TNF-α antibody; (3) a negative control with the
UV-O activated NFM; and (4) the conditioned cell culture medium alone. Each system was placed in
sterile Eppendorf tubes and 2 mL of monocyte-derived macrophage conditioned medium was added
individually, and kept at 37 ◦C in agitation in an orbital shaker at 120 rpm. Initially, a 3 days assay was
performed with a 1 ng/mL TNF-α concentration from monocyte-derived macrophage conditioned
medium. A specimen was collected at the following time points (2, 4, 6, 8, 10, 12, 24, 32, 48, and 72 h of
incubation) without conditioned medium replacement. Afterwards, a 15-day assay was conducted,
where a sample was collected daily and recharged with the same volume of recovered cell culture
medium each day, which had a TNF-α concentration of 500 pg/mL. This concentration was chosen
due to being closer to TNF-α levels in active RA patients (76.1 ± 103.2 pg/mL) [19], considering a
margin of error affected by the TNF-α degradation.
Enzyme-Linked Immunosorbent Assay (ELISA)
For the quantification of TNF-α in the conditioned medium at each time point, sandwich TNF-α
ELISA (KHC3012, TermoFisher Scientific, Carlsbad, CA, USA) was performed according to the
manufacturer. Absorbance was read at 450 nm on a microplate reader (Synergy HT, BioTek, Winooski,
VT, USA). A standard curve was built with concentrations ranging from 0 to 1000 pg/ml. The final
concentrations were calculated by subtracting the value of each sample (i.e., testing conditions 1–3) to
the conditioned culture medium baseline (i.e., testing condition 4), and the average was plotted for
each testing condition along time.
2.6. Biological Assays
2.6.1. Isolation and Cell Culture
Cartilage tissue consists of only one cell type, the chondrocyte, embedded in a dense extracellular
matrix (ECM). To evaluate the cytotoxicity of the developed biofunctionalized nanofibrous substrates,
human articular chondrocytes (hAC) isolated from knee cartilage samples, collected from arthroplasties
surgeries biopsies, were used. These cells were chosen as they were isolated from diseased joints
cartilage. Samples were collected under the cooperation agreement between Centro Hospitalar do
Alto Ave, Guimarães, Portugal, and the 3B’s Research Group, after informed donor consent. Briefly,
cells were isolated by enzymatic digestion, according to the protocol described previously [46].
Dulbecco’s modified Eagle’s medium (DMEM, Sigma D5671), containing 10 mM Hepes buffer
(Life Technologies, Paisley, UK), L-alanyl-L-glutamine (Sigma), Non Essential Aminoacids (Sigma)
10,000 units/ml penicillin, 10,000 µg/mL streptomycin, and 10% foetal calf serum was the basis for the
expansion and differentiation medium used herein (Basic medium). Basic medium was supplemented
with 10 ng/mL of bFGF for hAC expansion. Basic medium was further supplemented with 1 mg/mL
of insulin and 1 mg/mL of ascorbic acid, when hAC were seeded onto the PCL NFM (differentiation
medium). These supplements enhanced extracellular matrix (ECM) deposition by the cultured hACs.
Human articular chondrocytes where used at passage 4. Expansion medium was changed
every 2 days until the cells reached a confluence of 90%. The cells were harvested and seeded
onto both the activated NFM, as well the NFM with the TNF-α antibody immobilized using the
differentiation medium.
2.6.2. Seeding onto NFMs
Electrospun PCL NFMs were sterilized by UV-O treatment. All the surface functionalization
and TNF-α antibody immobilization steps were performed in sterile conditions. For the
biofunctionalized NFMs, antibody immobilization was performed overnight, and after the BSA
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blocking step, cell seeding was performed. Activated and biofunctionalized electrospun NFMs were
used as controls.
Confluent hACs were detached from the culture flask using trypsin, counted on a hemocytometer
and seeded at a density of 200.000 cells/NFM. Seeding was performed using the droplet method,
using a 50 µL drop of cell suspension on all sample groups in 24-well plates. The plates were
placed at 37 ◦C and 5% CO2 over 4 hours. After cell attachment to the NFMs, 1 mL of expansion
medium was added to each well. Afterwards, the medium was changed into differentiation medium.
The seeding was performed in three independent experiments. For each independent experiment,
constructs were cultured for 1, 14, 21 and 28 days under static conditions and collected at each time
point for quantification of cell viability, DNA, total protein analysis, as well as GAGs deposition.
Cell morphology was evaluated by SEM.
2.6.3. DNA Quantification
DNA quantification was assessed using Quant-iT™ PicoGreen® dsDNA Reagent and Kit
(Life Technologies, Eugene, OR, USA), according to the manufacturer´s instructions. Triplicates
of each condition collected at 1, 14, 21 and 28 days were evaluated. The specimens were collected,
1 mL of sterile distilled water was added, and then samples were stored at −80 ◦C until further
analysis. Prior quantification, the samples were defrosted and sonicated for 15 min. To extrapolate the
DNA values for each sample, a set of standards were prepared with concentrations ranging from 0
to 1.5 µg/mL. The fluorescence of each sample was measured on an opaque 96-well plate using an
excitation of 485/20 nm and an emission of 528/20 nm, using a microplate reader (Synergy HT, BioTek,
Winooski, VT, USA).
2.6.4. Total Protein Synthesis Quantification
Total protein was performed using Micro BCA™ Protein Assay Kit (ThermoFisher Scientific,
Rockford, IL, USA) according to the manufacturer´s instructions. Triplicates of each condition collected
at 1, 14, 21, and 28 days were evaluated. The samples were collected as described in Section 2.6.3.
A standard curve was prepared ranging from 0 to 200 µg/mL. The absorbance of each sample was
measured at 562 nm using a microplate reader (Synergy HT, BioTek, Winooski, VT, USA).
2.6.5. Glycosaminoglycan (GAG) Quantification
GAG quantification was performed using papain digestion. Triplicates of each condition collected
at each previously established time point were tested. The samples were collected and stored in
eppendorf tubes at −80 ◦C until further analysis. Digestion solution was prepared by adding papain
(Sigma Aldrich, Saint Louis, MO, USA) and N-acetyl cysteine (Sigma Aldrich) at concentrations of
0.05% and 0.096%, respectively, to 50 mL of digestion buffer (200 mM of phosphate buffer containing
1 mM EDTA (Sigma Aldrich), pH 6.8). Each specimen was incubated with 600 µL of digestion
buffer, overnight at 60 ◦C. After a 10-min centrifugation at 1300 rpm, the supernatant was collected.
Dimethymethylene Blue (DMB) stock solution was prepared dissolving 16 mg of DMB powder in
900 mL of distilled water containing 3.04 g of glycine and 2.73 g of NaCl. pH was adjusted to 3.0
with HCl and the volume adjusted to 1 L. The solution was stored at RT covered by aluminum foil.
Chondroitin sulphate (Sigma, C8529) solution was prepared in water in a 5 mg/mL stock solution and
kept refrigerated. Standards were prepared from serial dilutions of this solution. Three samples per
condition were considered per time point, and the absorbance of each sample was measured at 530 nm
using a microplate reader.
2.6.6. Histological Analysis
Samples were collected at the end of the experiment and processed for histology. Samples were
then fixed in 10% neutral-buffered formalin and then kept at 4 ◦C until the staining procedures. Alcian
Blue staining was performed by rinsing the samples in 3% acetic acid, keeping them in 1% alcian blue
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solution (Sigma, A-3157) for 1 h. After that, the stain was poured off and sections were washed with
water, let to dry, and then rinsed in absolute alcohol, cleared in xylene, and mounted in Entellan rapid
(Merck Millipore, Darmstadt, Germany, 1.07960.0500).
2.7. Statistical Analysis
Statistical analysis of values related with antibody immobilization, TNF-α capturing profiles
and biological studies was performed using IBM SPSS software (version 21; SPSS Inc., Armonk, NY,
USA). Firstly, a Shapiro-Wilk test was used to ascertain the assumption of data normality. For antibody
immobilization, protein capture and biological assays, the results showed that the data was not
following a normal distribution. P values lower than 0.01 were considered statistically significant in
the analysis of the results. A Kruskal-Wallis test was also performed for the comparison of more than
two independent groups of samples for one variable.
3. Results and Discussion
3.1. Antibody Immobilization Efficiency
The primary antibody (anti-TNF-α antibody) immobilization at the surface of electrospun
nanofiber meshes (NFMs) was performed in a wide range of concentrations (0–12 µg/mL) to
determine the maximum antibody immobilization capacity. The fluorescence of the unbound
secondary antibody was measured and the values were plotted against the various primary antibody
concentrations (Figure 1). As this is an indirect quantification method, higher fluorescence values of
the unbound secondary antibody correspond to lower concentrations of anti-TNF-α primary antibody
immobilization. Moreover, when the substrate is saturated, the fluorescence values of unbound
secondary antibody reach a plateau, despite the increment on antibody concentration.
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Figure 1. Box plot of anti-TNF-α antibody immobilization at concentrations ranging from
0 to 12 µg/mL. Data were analysed by nonparametric way of a Kruskal-Wallis test followed by Tukey’s
HSD test: (a) denotes significant differences compared to concentration 0, (b) denotes significant
differences compared to concentration 1, (c) denotes significant differences compared to concentration 2,
and (d) denotes significant differences compared to concentration 4.
The statistical analysis showed that the immobilized primary antibody, with concentrations above
4 µg/mL, displayed significantly lower values of fluorescence intensity than 0 µg/mL (p < 0.01).
Concentrations of 6 µg/mL and 8 µg/mL exhibited significantly lower values of fluorescence intensity
when compared to all lower concentrations (p < 0.001). Moreover, these two concentration values
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did not display differences between themselves. Finally, when the antibody was immobilized at a
concentration of 12 µg/mL, the fluorescence intensity of secondary antibody did not present significant
differences when compared to the fluorescence intensity of NFMs with primary antibody immobilized
at concentrations above 2 µg/mL (p < 0.01). Therefore, primary antibody immobilization at the surface
of the nanofibrous substrate reached a maximum concentration of 6 µg/mL, since no statistically
significant differences were found between the concentrations above. This value is within the range
of concentrations systemically administrated in clinical practice using Infliximab (3–10 mg/kg or
3–10 µL/mL, considering water as body mass) [52].
3.2. Spatial Distribution of the Antibody at the Surface of Electrospun Nanofibers
After the optimization of the anti-TNF-α antibody immobilization, its spatial distribution at the
surface of electrospun NFMs was evaluated by fluorescence microscopy (Figure 2). The fluorescence
images display a random mesh-like arrangement comparable to the typical morphology of the
electrospun NFM (Figure 2A), showing that the antibody immobilization was successfully performed
and uniformly distributed along the surface of the nanofibers (Figure 2B). To ensure that the secondary
antibody was only bound to the immobilized primary antibody, a control experiment was defined,
in which all biofunctionalization steps were performed, except for incubation with the primary
antibody. The absence of a fluorescent signal proves that Alexa Fluor 488® secondary antibody was
not immobilized at the surface of activated and functionalized NFMs (data not shown), confirming the
specific bond between the primary and secondary antibodies.
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3.3. Quantification of Available Amine Groups
Antibody immobilization was achieved by the amine groups inserted at the nanofibers’ surface,
which provides binding sites. Consequently, the availability of this functional group influences
directly the primary antibody immobilization. To confirm the success of aminolysis functionalization,
as well as to determine if the binding points were enough for primary antibody immobilization,
quantification of available amine groups was performed. For this, SH groups were inserted at the
surface of the aminolysis-treated NFMs and determined by the Ellman’s reagent method [49]. Table 1
presents SH groups quantification at the surface of bare, UV-O irradiated, aminolysis-treated, and fully
biofunctionalized (with primary antibody immobilized) NFMs. The concentration of free SH groups at
the surface of electrospun NFMs is at its maximum value for the aminolysis-treated NFM, whereas
the bare NFM presents the minimum value, as expected. These values are in agreement with the
ones described in the literature [49] and confirm that the insertion of amine groups was successful.
Moreover, it was also proved that the amine groups inserted at the surface of activated NFM were
enough for primary antibody immobilization, since free amine groups were still present. Indeed,
only around 48% of the inserted amine groups were used in the immobilization of the TNF-α antibody
at 6 µg/mL.
Nanomaterials 2019, 9, 567 9 of 16
Table 1. Quantification of the free SH groups at the surface of untreated, activated, aminolys-treated,
and biofunctionalized NFMs.
Condition SH/NH2 Groups [mol/cm]
Untreated (3.54 ± 5.61) × 10−9
UV-O activated (5.86 ± 1.12) × 10−9
Aminolysis-treatment (17.9 ± 6.06) × 10−9
Immobilized Antibody (8.65 ± 3.41) × 10−9
3.4. Quantification of Captured TNF-α
The ultimate goal of this work was to engineer a system that could capture TNF-α. Accordingly,
after the primary antibody immobilization optimization, the TNF-α capturing capacity of the
biofunctionalized substrate was assessed. A TNF-α rich conditioned culture medium from stimulated
monocyte-derived macrophages was used over two distinct time intervals: 3 days representing the
half-life of the anti-TNF-α antibody and 15 days representing the time interval of anti-TNF-α antibody
administration in the clinic. Four conditions were tested and compared: (1) the biofunctionalized NFM
(with primary antibody); (2) a positive control with the soluble form of the anti-TNF-α; (3) a negative
control with UV-O activated NFM; and (4) the conditioned culture medium alone. The quantification
of TNF-α levels from the conditioned culture medium (condition 4) was used as a baseline, eliminating
the quantification of degraded TNF-α but not captured. Therefore, to guarantee the values’ accuracy
and reproducibility between experiments, the values herein presented do not correspond to the ones
quantified by ELISA, but just to the concentration of the TNF-α captured.
3.4.1. TNF-α Capturing during 3 days
The proposed system comprising anti-TNF-α immobilized at the surface of NFMs (NFM + Ab)
was found to capture soluble TNF-α in significant amounts after 8 hours of incubation when compared
to the UV-O activated NFM (NFM) (p < 0.01) (Figure 3). This observation was also valid when the
biofunctionalized substrate was compared to the soluble antibody (sAb), as the NFM + Ab exhibited
significantly higher cytokine clearance for time points above the 10th hour of incubation (p < 0.01).
In addition, no significant differences were found between the sAb and the control condition UV-O
activated NFM (NFM).
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Figure 3. TNF-α captured (median and interquartile range) over 72 h. Data were analysed by
nonparametric way of a Kruskal-Wallis test, followed by Tukey’s HSD test: (a) denotes significant
differences compared to immobilized anti -α at the surface of electrospun NFM (condition
NFM + Ab).
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The initial efficiency of the activated NFM over the TNF-α levels at early time points might
be justified by the presence of free binding sites (such as the available amine groups quantified
in Section 2.4) that unspecifically immobilize/adsorb proteins present in the conditioned medium,
including TNF-α. Nevertheless, the capturing levels in this condition stabilize around zero for time
points above 6 hours, unlike the biofunctionalized NFM + Ab, which maintains the capturing ability
until the last time point. Likewise, the positive control sAb has a similar biological effect to the NFM
+ Ab testing condition during the first 10 hours. The sAb capturing ability decreases after this time
point and becomes comparable to the NFM negative control condition. These results show that the
immobilized form of anti-TNF-α is more stable and has longer action times, when compared to the
non-immobilized one (i.e., sAb). However, this decrease might be partially justified by the gradual
clearance of the soluble anti-TNF-α from the conditioned medium along the samples collection. It is
envisioned that this decrease of sAb mimics its clearance in a living system, since the circulating
antibody has higher propensity to be cleared by biological means [41]. Even if the sAb was locally
administered, part of it would escape the articular cavity and enter into circulation, suffering also the
clearance phenomena.
3.4.2. TNF-α Capturing during 15 Days
To confirm the efficiency of the primary antibody immobilized at the NFMs’ surface to clear TNF-α
from the conditioned medium over time, as well as to evaluate the action time of the immobilized
antibody, an extended assay (15 days) was performed. Experimental results show that the sAb only has
a biological effect for the first 3 days, since from the fourth time point on, it does not present significant
differences when compared to the UV-O activated NFM (Figure 4). The NFM + Ab has a significantly
higher antigen-neutralizing activity ranging from the 2nd day until the 11th day when compared to the
sAb condition. Moreover, the biofunctionalized NFM + Ab does not have a significant biological effect
from the 11th day on, as no significant differences were found when compared to the control NFM.
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Figure 4. TNF-α captured (median and interquartile range) over 15 days. Data were analyzed by
nonparametric way of a Kruskal-Wallis test, followed by Tukey’s HSD test: (a) denotes significant
differences compared to immobilized anti-TNF at the surface of electrospun NFM (condition NFM
+ Ab); and (b) denotes significant differences compared to soluble anti-TNF (condition sAb).
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These results confirm the initial hypothesis that the immobilization of the primary antibody at the
NFMs’ surface had a longer effect than the soluble antibody. This longer effect might be supported
by the increased stability that the antibody immobilization provides [53]. Moreover, the physical
attachment prevents the antibody clearance from the system by biological means. As each NFM
has a high specific surface area, it allows the immobilization of high concentrations of primary
antibody, requiring a small amount of material for the development of an effective cytokine capture
system. Moreover, as the NFMs are made of polycaprolactone (PCL), a well-known biodegradable
polymer, these membranes will be completely degraded within a maximum period of 2 years. Thus,
the degradation time ensures that the captured TNF-α, as well as the attached antibody, may be slowly
degraded/metabolized by biological processes and that there is no abrupt release of these molecules
to the exterior of the synovial cavity.
3.5. Biologic Assays
After the successful assembly of the TNF-capturing system, we then tested it in contact with
arthritic joint cells. Therefore, the toxicity of the biofunctionalized NFMs was assessed by culturing
them with human articular chondrocytes (hACs). These cells were isolated from diseased knee
arthroplasties, thus presenting a phenotype that is associated with RA and osteoarthritis pathologies,
where inflammation was present. Different biological assays were conducted to assess the hACs
morphology, proliferation, total protein, and glycosaminoglycans (GAGs) synthesis. hACs were
cultured at the surface of three different substrates: (1) anti-TNF-α antibody immobilized at the surface
of NFMs (NFM + Ab), (2) UV-O activated NFM (NFM) and (3) tissue culture polystyrene (TCPs)
as positive control. The influence of the anti-TNF-α immobilization at the surface of NFMs over
hACs morphology was assessed by SEM. Micrographs (Figure 5) showed that hACs maintained their
round-shape morphology, typical of these chondrocytic cells.
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Chondrocytes proliferation was also evaluated by quantifying the dsDNA concentration.
Experimental results showed that the TCP’s condition displayed a significantly higher DNA
concentration, for 14 and 28 days of culture, when compared to all other culture conditions (p < 0.001)
(Figure 6A). Furthermore, on the 1st and 21st days of hACs culture, the control condition (TCPs)
present similar proliferation to the NFM + Ab testing condition. Finally, the NFM condition presented
a significantly lower cell proliferation at 21 and 28 days of culture, when compared to the NFM +
AB condition (p < 0.001). Taken together, these results indicate that the immobilized anti-TNF-α may
inhibit chondrocytes growth by mimicking an inflammatory environment, where cells would respond
by limiting their growth and proliferation. This effect is not negative, since our primary goal was
not to promote an extensive cell proliferation, but merely to assess the device’s potential cell toxicity.
Nevertheless, hACs keep proliferating, even if at a lower rate when compared to the controls. Indeed,
IL1-β and TNF-α have been shown to inhibit the migratory potential of chondrogenic progenitor cells
in osteoarthritic cartilage [54]. Furthermore, OA-derived hACs cultures have been reported to excrete
around 3000 pm/µL of TNF-α [55], thus these cells have mechanisms to respond to high concentrations
of this cytokine in the surrounding environment.
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Figure 6. Box plot of human articular chondrocytes proliferation (A) and protein synthesis (B)
when cultured on tissue culture polystyrene (TCPs), UV-O treated electrospun PCL NFM (NFM)
and anti-TNF-α immobilized at the NFMs’ surface (NFM + Ab). Data were analysed by nonparametric
way of a Kruskal-Wallis test, followed by Tukey’s HSD test: (a) denotes significant differences compared
to NFM + Ab and (b) denotes significant differences compared to NFM.
Quantification of total protein synthesis is presented in Figure 6B. Experimental data showed that
TCP’s control condition displayed significantly higher concentration values than all the other testing
conditions for the 1st and 21st days of culture (p < 0.01). On the other hand, the NFM + Ab testing
condition displayed a significantly lower protein concentration when compared to all other culture
conditions for 28 days of culture (p < 0.01). At 14 days of hACs culture, no significant differences
between conditions were found (p = 0.148). The protein synthesis in the NFM + Ab condition was
lower for longer culture periods, which is possibly due to the extracellular accumulation of proteins by
hACs, rather than the intracellular synthesizing rate.
Furthermore, the impact of the anti-TNF-α antibody immobilization at the surface of NFMs on
GAG production and accumulation (Figure 7A) by hACs was also assessed. No significant differences
were found between all culture conditions for the 1st (p = 0.186) and 14th days (p = 0.088) of the
experiment. On the 21st day, the NFM + Ab testing condition displayed significantly lower GAG
concentrations than control condition TCPs (p < 0.01). Moreover, on the 28th day, TCPs presented
significant higher GAGs concentration than all other culture conditions (p < 0.01). Concerning the
GAGs production by hACs cultured onto the NFM + Ab, the obtained results confirm the evidences
found in the intracellular protein synthesis. There is a decrease in the total protein concentration values
for longer time points, with a concomitant increase of GAGs production for these same periods of time,
indicating that protein synthesis was being directed by the GAGs production. This increase of GAGs
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concentration for late time points of the experiment are in accordance to our hypothesis, as they will
protect chondrocytes against the inflammatory environment.Nanomaterials 2019, 9, x FOR PEER REVIEW 13 of 16 
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(b) denotes significant differences compared to NFM. Alcian blue staining evidencing sulphated
proteoglycans deposition i samples from TCPs (B), NFMs (C), and NFM + Ab (D) on the 28th day of
the experiment.
As it can be observed in Figure 7B–D, sulphated proteoglycans, an important component of
articular cartilage ECM, were detect d on all c lture conditions by alcian blue staining. Furthermore,
these obse vations are reassured by the quantification of GAG presented in the box plot of Figure 7A.
Altogeth , these results on intra- and extra-cellular protein synthesis confirmed that hACs are not only
able to proliferate and maintain their typical ound mor h logy, bu are also capable of performing
their metabolic functions properly, the pr sence of the NFM + Ab testing system. With this study,
we validated the use of this TNF-α ca turing system nearby cartilaginous structures. There is, indeed,
an influence on these parameters when cells are cultured onto NFM + Ab nanofibers, but it is not
enough to restr i human articular chondrocytes fu ctions. In fact, it has been described that the
blockade of TNF-α by Infliximab treatment, during fractur healing, leads to an increas d callus size.
This increase was accompanied by an increase in cartilage tissue [56].
4. Conclusions
The present work proposes the use of nanofibrous meshes (NFM) functionalized with a
neutralizing a ti-TNF-α antibody, for the selective clearance of TNF-α. From a spectrum of primary
antibody concentrations, 6 µg/mL was determined as the maximum im obilization capacity of a
UV-O activated and aminolysis-functionalized NFM. Experimental results demonstrated the bioactivity
of the developed biofunctio al substrate on clearing TNF-α from conditioned culture medium
of macrophages and a longer time of action whe compared to the circulating/soluble antibody.
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Furthermore, cell biology data showed that the immobilized anti-TNF-α antibody exhibited no
cytotoxicity over human articular chondrocytes and that these cells were able to maintain their
metabolic functions in the presence of the TNF-capturing system. In conclusion, we herein describe
an effective system for local clearance of TNF-α, which is particularly relevant in a RA scenario,
but adaptable to other autoimmune inflammatory conditions.
5. Patents
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